Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31310223 | 0.85 | KDM1A (0.55) | KDM1ASMYD3KMT2AL3MBTL1MEN1 | |
| SCHEMBL1023353 | 0.82 | L3MBTL1 (0.62) | KDM1ASMYD3KMT2AL3MBTL1MEN1 | |
| SCHEMBL1021945 | 0.78 | CHRM3 (0.53) | KDM1AKMT2ASIGMAR1 | |
| SCHEMBL28197914 | 0.78 | EZH2 (0.57) | KDM1ASMYD3KMT2AL3MBTL1MEN1 | |
| SCHEMBL1017858 | 0.78 | KMT2A (0.52) | KDM1AKMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL31746215 | 0.75 | SMN1; SMN2 (0.43) | KDM1ALMNANPC1RAB9ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL17002785 | 0.73 | KDM1A (0.76) | KDM1A | |
| Hydrochloric Acid SCHEMBL17002782 | 0.73 | KDM1A (0.76) | KDM1A | |
| SCHEMBL31310157 | 0.73 | KDM1A (0.59) | KDM1ASMYD3KMT2AL3MBTL1MEN1 | |
| SCHEMBL6842252 | 0.73 | ALDH1A1 (0.59) | SMYD3KMT2AL3MBTL1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101848899-B | As the N-benzyl of LXR conditioning agent, N '-aryl carbonyl bridged piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2016-03-02 | — | — | CN | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| CN-101848899-A | N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators | ORGANON NV | 2010-09-29 | — | — | CN | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | KDM1A 4398/4885SMYD3 4588/4885KMT2A 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.